Presbyopia Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examines DelveInsight | Key Companies – Eyenovia, Orasis Pharmaceutical, Ocuphire Pharma, Novartis

November 14 23:25 2022
Presbyopia Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examines DelveInsight | Key Companies - Eyenovia, Orasis Pharmaceutical, Ocuphire Pharma, Novartis
The Presbyopia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Presbyopia pipeline products will significantly revolutionize the Presbyopia market dynamics.

DelveInsight’s “Presbyopia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Presbyopia, historical and forecasted epidemiology as well as the Presbyopia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Presbyopia market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

 

To Know in detail about the Presbyopia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Presbyopia Market Insights

 

Presbyopia Overview

According to American Academy of Opthalmology, Presbyopia is a normal part of aging wherein your eyes gradually lose the ability to see things clearly up close. The term “presbyopia” comes from a Greek word which means “old eye.” Most people begin to notice the effect of presbyopia sometime after the age of 40 as the lenses of the eyes naturally lose their elasticity due to the aging process.

 

Some of the key facts of the Presbyopia Market Report: 

  • The Presbyopia market size was valued at USD 17,883 Million in the year 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032) 
  • According to the American Optometric Association though Presbyopia usually becomes visible in the early to mid-40s, but the reduction in the vision of an individuals’ focus starts as early as childhood. 
  • The total prevalent cases of Presbyopia in the 7MM was found to be approximately 289,136,235 cases in 2021. These cases are expected to increase by 2032 
  • Among the 7MM, the United States had the highest prevalent cases of Presbyopia with approximately 118,346,762 cases in 2021 
  • Key Presbyopia Companies: Eyenovia, Orasis Pharmaceutical, Ocuphire Pharma, Novartis, Visus Therapeutics, Lenz Therapeutics, Abbvie, and others
  • Key Presbyopia Therapies: MicroLine, CSF-1, Nyxol, UNR844, VT-101, Brimochol, LNZ100, AGN-241622, and others 
  • The Presbyopia epidemiology based on gender analyzed that the prevalence of Presbyopia is higher in females than in males 

 

Get a Free sample for the Presbyopia Market Report

 

Key benefits of the Presbyopia Market report:

  1. Presbyopia market report covers a descriptive overview and comprehensive insight of the Presbyopia Epidemiology and Presbyopia market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Presbyopia market report provides insights on the current and emerging therapies.
  3. Presbyopia market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Presbyopia market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Presbyopia market.

 

Download the report to understand which factors are driving Presbyopia epidemiology trends @ Presbyopia Epidemiological Insights 

 

Presbyopia Market  

The dynamics of the Presbyopia market are anticipated to change in the coming years owing to the expected launch of emerging therapies such and others during the forecasted period 2019-2032. 

“The pipeline for Presbyopia is dynamic, consisting of Orasis Pharmaceuticals (PresbiDrops), Novartis (UNR844), Eyenovia (MicroLine), AbbVie (AGN-241622), Ocuphire Pharma (Nyxol), Visus therapeutics (Brimochol), and others, most of which are expected to launch during the forecast period [2022-2032]” 

 

Presbyopia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Presbyopia Epidemiology Segmentation:

The Presbyopia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Presbyopia
  • Prevalent Cases of Presbyopia by severity
  • Gender-specific Prevalence of Presbyopia
  • Diagnosed Cases of Episodic and Chronic Presbyopia

 

Presbyopia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Presbyopia market or expected to get launched during the study period. The analysis covers Presbyopia market uptake by drugs, patient uptake by therapies, and sales of each drug.  

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Presbyopia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Discover more about therapies set to grab major Presbyopia market share @ Presbyopia market forecast 

 

Presbyopia Therapies and Key Companies

  • MicroLine: Eyenovia
  • CSF-1: Orasis Pharmaceutical
  • Nyxol: Ocuphire Pharma
  • UNR844: Novartis
  • VT-101/Brimochol: Visus Therapeutics
  • LNZ100: Lenz Therapeutics
  • AGN-241622: Abbvie

 

Presbyopia Market Drivers

  • Rising prevalence of Presbyopia
  • An upsurge in launch of products
  • Increasing lifestyle changes
  • Increasing research in pharmaceutical treatment
  • Increase in geriatric population

 

Scope of the Presbyopia Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Presbyopia Companies: Eyenovia, Orasis Pharmaceutical, Ocuphire Pharma, Novartis, Visus Therapeutics, Lenz Therapeutics, Abbvie, and others
  • Key Presbyopia Therapies: MicroLine, CSF-1, Nyxol, UNR844, VT-101, Brimochol, LNZ100, AGN-241622, and others
  • Presbyopia Therapeutic Assessment: Presbyopia current marketed and Presbyopia emerging therapies
  • Presbyopia Market Dynamics: Presbyopia market drivers and Presbyopia market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Presbyopia Unmet Needs, KOL’s views, Analyst’s views, Presbyopia Market Access and Reimbursement 

 

Presbyopia Market Barriers

  • Rising healthcare costs
  • Shortage of trained ophthalmologists
  • Lack of accessibility of eye care services
  • Limitations of Monovision

 

Table of Contents 

1. Presbyopia Market Report Introduction

2. Executive Summary for Presbyopia

3. SWOT analysis of Presbyopia

4. Presbyopia Patient Share (%) Overview at a Glance

5. Presbyopia Market Overview at a Glance

6. Presbyopia Disease Background and Overview

7. Presbyopia Epidemiology and Patient Population

8. Country-Specific Patient Population of Presbyopia 

9. Presbyopia Current Treatment and Medical Practices

10. Presbyopia Unmet Needs

11. Presbyopia Emerging Therapies

12. Presbyopia Market Outlook

13. Country-Wise Presbyopia Market Analysis (2019–2032)

14. Presbyopia Market Access and Reimbursement of Therapies

15. Presbyopia Market Drivers

16. Presbyopia Market Barriers

17.  Presbyopia Appendix

18. Presbyopia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

To know more about Presbyopia treatment, visit @ Presbyopia Medications  

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com